Anupam Rasayan India Limited announces an acquisition

The acquisition implies an enterprise value of approximately Rs 3,131 Cr for 100% of Bliss GVS Pharma. The announced purchase consideration is lower—approximately Rs 2,192 Cr, rounded to Rs 2,200 Cr—for the 43.3% block purchase plus the 26% open offer.

Deal value and funding mix

The funding is not separately disclosed as an internal-cash-versus-debt split. The disclosed source-of-funds mix is:

• Term loan: approximately Rs 300 Cr ^[3]
• Non-controlling, non-voting equity instrument: approximately Rs 1,892 Cr, calculated as Rs 2,191.85 Cr less the Rs 300 Cr term loan ^[3]
• On the announced consideration, this is approximately 13.69% debt and 86.31% equity-like funding, derived from the disclosed amounts.

Impact on Anupam Rasayan’s net debt-to-equity

Anupam Rasayan’s FY26 consolidated net debt-to-equity ratio was 0.43x ^[4], based on net debt of approximately Rs 1,436.6 Cr ^[5] and total equity of approximately Rs 3,333.8 Cr ^[6].

Assuming the Rs 300 Cr term loan is incremental and the balance equity instrument is recognised within consolidated equity:

• Pro forma net debt = Rs 1,436.6 Cr + Rs 300 Cr = Rs 1,736.6 Cr
• Pro forma equity = Rs 3,333.8 Cr + Rs 1,891.85 Cr = Rs 5,225.65 Cr
• Pro forma net debt-to-equity = approximately 0.33x, derived from those inputs.

Thus, on a financing-only basis, the transaction would reduce reported leverage from 0.43x to roughly 0.33x, because most of the consideration is funded through the equity instrument rather than debt. If that instrument is ultimately classified as a liability rather than equity, the ratio would instead be approximately 0.52x; therefore, 0.33x is a pro forma estimate, not a reported post-acquisition ratio.

The definitive agreement, as disclosed, is an equity acquisition rather than a separately itemised transfer of manufacturing assets or intellectual property.

• Anupam Rasayan, through wholly owned subsidiary Mates Visa Consultancy, acquired a 48.2% controlling stake in Bliss GVS Pharma at Rs 299 per share. The agreement was signed on 23 May 2026, followed by a mandatory open offer; the transaction was subsequently completed. ^[7]
• Funding comprised a Rs 300 Crores term loan and approximately Rs 1,450 Crores through non-controlling, non-voting instruments. ^[7]
• The announcement does not specify separate consideration, conveyance mechanics, licensing arrangements, or conditions for transferring Bliss GVS’s manufacturing assets or intellectual property. It only identifies Bliss GVS’s underlying operating platform: more than 150 brands and six Maharashtra manufacturing facilities certified by US FDA, EU-GMP and WHO-GMP. ^[7]

Revenue contribution

A separate FY27 projected revenue-mix contribution from Bliss GVS was not disclosed. The company provided only a pro-forma combined-revenue bridge:

• Bliss GVS pro-forma revenue: Rs 927 Crores
• Combined pro-forma revenue: more than Rs 4,000 Crores ^[8]

This implies a pro-forma revenue contribution of less than approximately 23.18% (`Rs 927 Crores / Rs 4,000 Crores`), with the actual percentage below that level because the stated combined revenue exceeds Rs 4,000 Crores. This is a steady-state pro-forma mix, not a forecast of Bliss GVS’s contribution to Anupam Rasayan’s reported consolidated revenue for FY27.

Bliss GVS has historically operated at a lower EBITDA margin than Anupam Rasayan’s existing business on a trailing basis, although the gap narrowed materially by FY26. The comparison below uses standalone margins for both companies, avoiding the distortion from Anupam’s consolidated subsidiaries and acquisitions.

Margin comparison

The key read-through is:

• Anupam’s underlying margin profile was generally stronger: its TTM standalone EBITDA margin remained above Bliss’s through the comparable FY26 periods.
• Bliss was improving: its TTM margin rose from 21.40% through Q2 FY26 to 24.40% through Q4 FY26, while Anupam’s declined from 27.40% to 25.40%. The spread therefore narrowed from 6.00 pp to 1.00 pp, derived from the reported margins above.
• Quarterly volatility was meaningful: Bliss exceeded Anupam in Q2 FY26, but Anupam was ahead in Q3 and Q4. Thus, Bliss should not be treated as a structurally low-margin asset; its FY26 exit profile was broadly approaching Anupam’s standalone level.

Management’s synergy timeline

Management indicated a two-stage timeline:

• Initial financial visibility: full synergy benefits and financial contribution were expected to become more visible going forward in FY27 ^[13].
• Broader operational synergy realization: management gave a broader estimate of approximately two to three years, after first consummating the transaction ^[14].

Management also indicated that Bliss would continue to operate as a separate entity while the two businesses leveraged each other’s capabilities, rather than being immediately folded into a single operating structure ^[13]. The implication is that FY27 represents the beginning of visible contribution, whereas the fuller benefit from product cross-selling, customer access, regulated-market expansion and operating integration is expected to build over a two-to-three-year period.